Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

AGEN vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

AGEN Overall Winner 6-Pillar Tally: AGEN 4 – 1 LCTX (1 Tie) Matrix Metrics: AGEN 8 – 2 LCTX

As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AGEN vs LCTX
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.14
-4.06% 1D
Market Cap $289.6M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.58β · 77% Vol
Unified Composite Score
54.2 / 100 HOLD
Tech 48.0 Fund 49.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $6.70 · SMA50: $7.28
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98

6-Pillar Scorecard Institutional Category Breakdown (AGEN 4 – 1 LCTX)

Columns: Metric · AGEN · LCTX
1. Valuation Multiples AGEN
Forward P/E 3.7x 30.7x
Trailing P/E 27.8x 30.7x
PEG Ratio 1.44x 10.64x
EV / Revenue 8.3x 16.3x
2. Growth & Scale AGEN
Revenue Growth (YoY) +4.1% -61.0%
Earnings Growth (YoY) -99.0% +0.0%
TTM Revenue (USD) $34M $11M
Market Cap $289.6M $212.1M
3. Profitability & Quality AGEN
Gross Margin N/A -95.0%
Operating Margin 38.9% -280.3%
Net Profit Margin 30.8% 16.2%
Return on Equity (ROE) -1278.8% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$35M -$24M
Cash Flow Margin -103.7% N/A
Net Cash / Leverage $9.3M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 167.5% (31st %ile) 896.2% (100th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) 1.10x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AGEN (8) vs LCTX (2)
Institutional Metric AGEN LCTX Criterion Row Edge
Market Capitalization
Scale
$289.6M $212.1M Larger Scale AGEN
Trailing P/E Ratio
Valuation
27.8x 30.7x Lower Multiple AGEN
Forward P/E Ratio
Valuation
3.7x 30.7x Lower Multiple AGEN
Revenue Growth (YoY)
Growth
+4.1% -61.0% Higher Growth AGEN
Operating Margin (TTM)
Profitability
38.9% -280.3% Higher Margin AGEN
Net Profit Margin
Profitability
30.8% 16.2% Higher Margin AGEN
Return on Equity (ROE)
Capital Efficiency
-1278.8% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
45% ($3–$10) 4% ($1–$2) Stronger Trend AGEN
Beta / 30D Volatility
Risk Regime
1.58β · 77% Vol 1.36β · 79% Vol Lower Realized Risk AGEN
Unified Institutional Score
Composite Signal
54.2 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$34M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.44x PEG · 8.3x EV/Rev 10.64x PEG · 16.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$35M ($9.3M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +9.76 pp
AGEN: -4.06% · LCTX: -13.82%
3M Horizon Tie
AGEN: -24.1% · LCTX: -24.07%
6M Horizon AGEN +132.18 pp
AGEN: +94.3% · LCTX: -37.88%
1Y Horizon AGEN +98.82 pp
AGEN: +45.15% · LCTX: -53.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AGEN Revenue LCTX Revenue AGEN Op. Margin LCTX Op. Margin Margin Leader
FY2018 $40M $0M -336.6% -837.9% AGEN
FY2019 $150M $0M -46.7% -1106.0% AGEN
FY2020 $90M $0M -133.0% -1448.4% AGEN
FY2021 $300M $0M 8.7% -1133.6% AGEN
FY2022 $100M $10M -183.0% -153.2% LCTX
FY2023 $160M $10M -102.1% -276.5% AGEN
FY2024 $100M $10M -116.4% -226.1% AGEN
FY2025 $110M $10M -17.7% -251.6% AGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AGEN BREAKDOWN
35d in phase · OBV NEUTRAL
Current IV 167.5%
IV Percentile 31st %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $289.6M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AGEN vs LCTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AGEN carries a Unified Composite Score of 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY). Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGEN leads the Growth & Scale pillar: AGEN posts +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AGEN cumulative revenue shifted +175.0% while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, AGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

AGEN screens cheaper on headline valuation multiples. AGEN trades at 3.7x Forward P/E, 27.8x Trailing P/E, 1.44x PEG, and 8.3x EV/Revenue (-103.7% FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGEN (-1278.8% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AGEN carries 167.5% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 77% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.